Spencer Pharmaceutical Inc. (SPPH) Makes Headway Into IAB MCSC Index
Online, October 27, 2010 (Newswire.com)
-
Spencer Pharmaceutical Inc. (PINKSHEETS: SPPH) announced today that it has been added to the ItsAllBull.net Micro Cap Small Cap (MCSC) Index. The MCSC Index is tracking the general performance of equities that trade primarily on the Over-the-Counter (OTC) markets including the Pinksheets, Bulletin Boards, as well as the TSX Venture Exchange. It has been over performing the Dow Jones and S&P TSX indices since its inception in September 2009.
You can also view its performance at: http://www.itsallbull.net/mcsc.php
On October 25, 2010, the company had begun licensing talks with several other pharmaceuticals to manufacture and distribute its Met4 formula in their respective regions. The company expects to be in a position to sign a memorandum of understanding and or licensing agreements on or before February 10, 2011. "Currently, SPPH trades at only 32 cents and could soon be seen making significant upside in the days ahead", as reported by the market experts.
Spencer Pharmaceutical Inc. is a US-based Pharmaceutical Research and Development Corporation, which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndrome.
This company was incorporated in 1998 and is based in Boston, Massachusetts. It has operations primarily in North America and Europe and specializes in developing drug platform technologies for the treatment of neurological deceases.
The company also specializes in the controlled release of existing therapeutic molecules in the areas of central nervous system, which include Alzheimer and Parkinson diseases, and brain cancer; and patented slow release drug delivery technology for the treatment of type-2 diabetes, arthritis, and other potential applications.
For the past twenty five years, Dr. Max Arella, President and CEO of Spencer Pharmaceutical Inc., has been working as a private consultant advising clients and businesses with technological and scientific development, innovative technology transfer and commercial development from university bench top to commercial developments. Over the years he has also acted as the president of a privately held Biotech company that successfully achieved business deals.
Recently Dr. Arella stated: "Spencer Pharmaceutical is now developing an Ibuprofen once a day monolithic tablet formulation permitting the reduction of several adverse effects preventing gastrointestinal complications (bleeding, ulceration or perforation) and or CV risks." This clearly shows the company's continuous strive towards development of innovative medicines.
Pleased with the development of the company's profile and its inclusion into ItsAllBull.net Micro Cap Small Cap (MCSC) Index Dr. Max Arella, CEO of Spencer Pharmaceutical Inc. said: "Clearly we are very pleased to be included in the IAB MCSC Index as it is very important to continually improve the company's profile and exposure."
A new audio interview featuring Spencer Pharmaceutical Inc. (Pinksheets:SPPH) is now available and can be heard here:Video
Related Media
